Calithera Biosciences, Inc. (NASDAQ:CALA) fell 6.3% on Wednesday after an insider sold shares in the company. The stock traded as low as $16.15 and last traded at $16.30, with a volume of 766,610 shares changing hands. The stock had previously closed at $17.40.
Specifically, VP Keith Orford sold 2,120 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 3,470 shares of company stock worth $61,817 in the last ninety days. Insiders own 16.30% of the company’s stock.
CALA has been the topic of a number of analyst reports. BidaskClub lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective (up previously from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $20.00 price objective (up previously from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $15.50.
The company has a 50-day moving average of $15.83 and a 200-day moving average of $12.92. The firm’s market capitalization is $514.40 million.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million for the quarter, compared to analyst estimates of $4.80 million. On average, analysts predict that Calithera Biosciences, Inc. will post ($0.83) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Calithera Biosciences during the first quarter valued at $117,000. Legal & General Group Plc bought a new stake in shares of Calithera Biosciences during the second quarter valued at about $120,000. Nationwide Fund Advisors bought a new stake in shares of Calithera Biosciences during the first quarter valued at about $131,000. KCG Holdings Inc. bought a new stake in shares of Calithera Biosciences during the first quarter valued at about $144,000. Finally, Paloma Partners Management Co bought a new stake in shares of Calithera Biosciences during the first quarter valued at about $160,000. 55.11% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/15/calithera-biosciences-inc-cala-stock-price-down-6-3-on-insider-selling-updated-updated-updated.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
